Physician profile
John Brendese
NPI 1407841901
$17,852.52
in general payments reported to CMS, 2019-2025
41 companies · $3,850 in 2025
The $3,850 reported for 2025 was more than what 82% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,814 · 2020: $2,175 · 2021: $1,533 · 2022: $1,048 · 2023: $1,528 · 2024: $1,904 · 2025: $3,850.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,142 · Consulting Fee: $2,140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,141.63 |
| Consulting Fee | $2,140.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $3,232.75 | 2019-2023 | Krystexxa |
| Amgen INC. | $3,056.41 | 2019-2025 | Enbrel, Otezla, Otezla |
| Sobi, INC | $2,252.91 | 2022-2025 | |
| Pfizer INC. | $1,207.30 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,197.44 | 2019-2025 | |
| Abbvie INC. | $1,153.92 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Ucb, INC. | $1,029.91 | 2019-2025 | Cimzia, Bimzelx |
| Glaxosmithkline, LLC. | $1,014.94 | 2019-2025 | Benlysta |
| Janssen Biotech, INC. | $878.95 | 2019-2025 | Tremfya, Simponi Aria, Remicade |
| Lilly USA, LLC | $810.33 | 2019-2024 | Taltz |
| E.R. Squibb & Sons, L.L.C. | $353.87 | 2019-2025 | Orencia |
| Astrazeneca Pharmaceuticals Lp | $272.73 | 2021-2025 | Saphnelo |
| Regeneron Healthcare Solutions, INC. | $187.49 | 2019 | |
| Genentech USA, INC. | $135.39 | 2019-2025 | Actemra, Gazyva |
| Genzyme Corporation | $129.79 | 2020-2023 |
Show all 40 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Brendese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.